Get started
Author

Hyeon Ji Park

Observed name: H. Park
ORCID: 0000-0002-2148-2171
Observed ORCID: 0000-0002-2148-2171
OpenAlex ID: A5081687815
Dienogest in endometriosis treatment: A narrative literature review
2023 · Joowon Lee, Hyeon Ji Park, et al. · Daehan saengsik uihak hoeji/Clinical and experimental reproductive medicine · 30
PDF
Robotic radical hysterectomy for cervical cancer: current trends and controversies
2024 · Jeeyeon Kim, Ha Kyun Chang, et al. · Journal of Cancer · 8
PDF
Identification of peptide inhibitors of matrix metalloproteinase 1 using an in-house assay system for the enzyme
2019 · Moon Won Min, Chae-Eun Kim, et al. · Enzyme and Microbial Technology · 8
Coupling hCG-based protease sensors with a commercial pregnancy test strip for simple analyses of protease activities
2023 · Hyeon Ji Park, Yuseon Kim, et al. · Biosensors and Bioelectronics · 7
One-pot colorimetric detection of molecules based on proximity proteolysis reaction
2021 · Hyeon Ji Park, Yuseon Kim, et al. · Biosensors and Bioelectronics · 6
Nucleic Acid Detection by a Target-Assisted Proximity Proteolysis Reaction
2018 · Hyeon Ji Park, Tae Hyeon Yoo · ACS Sensors · 6
A colorimetric protease activity assay method using engineered procaspase-3 enzymes
2016 · Dokyung Yang, Hyeon Ji Park, et al. · Analytical Methods · 4
ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al. · Molecular Cancer Therapeutics · 1
622MO An asymmetrical CLL1/CD3 bispecific antibody, ABL602, exhibits CLL1 binding-dependent CD3 binding/activation and antitumor activity in acute myeloid leukemia (AML) mouse model and leukemia blasts from AML patients
2022 · E. Lee, Y. Lim, et al. · Annals of Oncology · 1
Development of one-step isothermal methods to detect RNAs using hairpin-loop signal converters and proximity proteolysis reaction
2021 · Hyeon Ji Park, Cheulhee Jung, et al. · Biosensors and Bioelectronics · 1
Assembly of bispecific antibodies in culture supernatants using split intein-mediated protein trans-splicing
2026 · Yeaji Lee, Kyungmoon Lee, et al. · Journal of Biological Engineering
Data from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S5 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 5 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S4 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S6 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 4 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S16 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S14 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 1 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Works count: 43
Citation count: 72
H-index: 6
I10-index: 1
Year
Topic
Type